theMednetRegister
  • Community
    • Overview
    • Experts
    • Editors
    • Fellows
    • Code of conduct
    • AI Guidelines for Physicians
  • Company
    • About Us
    • FAQs
    • Privacy Policy
    • Terms of Use
    • Careers
    • Programs
  • News
    • News Releases
    • Press Coverage
    • Publications
    • Blog
  • Contact Us
  • Sign in

Rheumatology

VEXAS   

Questions discussed in this category


For patients with VEXAS syndrome and good response to azacitidine, what duration of therapy do you consider?
How do you decide to trial a patient off treatment? When do you consider spacing therapy and at what frequency?
1 Answer available

Which other agent would you consider for a patient with VEXAS who has failed methotrexate, multiple TNF inhibitors, Tocilizumab, and Ruxolitinib?
1 Answer available
2059418418


Papers discussed in this category


Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2022 Oct 17
VEXAS Syndrome-A Review of Pathophysiology, Presentation, and Prognosis.

Blood, 2022 Aug 25
Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study.

Annals of the rheumatic diseases, 2024 Sep 30
Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX.

Related Topics in Rheumatology

  • Lung Cancer
  • Breast Cancer
  • Head and Neck Cancers
  • Hematologic Malignancies
  • Radiation Oncology
  • Gynecologic Oncology
  • Palliation
  • Neuro-Oncology
  • Gastrointestinal Cancers
  • Genitourinary Cancers

Copyright © 2025 theMednet
All Rights Reserved.